Slide 1: Fourth Quarter and Year-End 2020 Financial Results & Business Update
Fourth Quarter and Year-End 2020 Financial Results & Business Update February 11, 2021 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the co
Slide 3: Agenda
Introduction Sandy Coombs, VP, Investor Relations Corporate Update Richard Pops, Chief Executive Officer Q4 & FY 2020 Financial Results; 2021 Financial Expectations Iain Brown, Chief Financial Officer Q4 & FY 2020 Commercial Review Todd Nichols, Chief Commercial Officer R&D Pipeline Update Richard P
Slide 4: Execution Against Our Strategic Priorities
Execution Against Our Strategic Priorities Commercial Execution VIVITROL® and ARISTADA® Strong performance in a complex environment Adapted commercial strategy in response to COVID-19 Prepared for synergistic launch of LYBALVI™ (ALKS 3831) within psychiatry portfolio Supported launch of VUMERITY® Ad
Slide 5: Focus on Value Creation in 2021: Three Key Components
Focus on Value Creation in 2021: Three Key Components Grow and Diversify Commercial Revenues Demonstrate Value of R&D Investments Manage for Growth & Long-Term Profitability Drive VIVITROL® and ARISTADA® net sales Support VUMERITY® growth Launch LYBALVI™ (PDUFA* June 1, 2021) Nemvaleukin alfa Determ
Slide 6: Full-Year 2020 Financial Results Summary
Full-Year 2020 Financial Results Summary 6 In millions In millions In millions Represents $150.0 million milestone payment from Biogen related to FDA approval of VUMERITY® in Q4 2019. ($37.8)* $1,020.9* *Amount excludes $150.0 million milestone payment from Biogen.
Slide 7: Fourth Quarter 2020 Revenue Summary
Fourth Quarter 2020 Revenue Summary 7 Amounts in the table above do not sum due to rounding. *Decrease in VIVITROL net sales in Q4 ‘20 was primarily due to COVID-19 pandemic-related disruptions. †Includes $5.2M of the $150M milestone payment from Biogen related to FDA approval of VUMERITY® recorded
Slide 8: 2020 Revenue Summary
2020 Revenue Summary 8 *Decrease in VIVITROL net sales in FY 2020 was primarily due to COVID-19 pandemic-related disruptions. †Includes $5.2M of the $150M milestone payment from Biogen related to FDA approval of VUMERITY® recorded as R&D revenue. ‡Includes $144.8M of the $150M milestone payment from
Slide 9: 2021 Financial Expectations
9 † These expectations are provided by Alkermes plc (the “Company”) in its Current Report on Form 8-K filed with the SEC on Feb. 11, 2021 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. * Ranges provided are based on re
Slide 10: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations FY’20 year-over-year net sales decline of 7% to $310.7M, driven by unit decline of 8% Gross-to-net deductions: 50% in FY’20, compared to 48% in FY’19 Minimal inventory build of approximately $1.5M in Q4’20 FY’21 net sales expected to range from $315M - $345M* E
Slide 11: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations FY’20 year-over-year net sales growth of 27% to $241.0M, driven by unit growth of 30% Gross-to-net deductions: 53% in FY’20, compared to 49% in FY’19 Inventory levels increased by approximately $5.2M in Q4’20 FY’21 net sales expected to range from $260M - $290M
Slide 12: ARISTADA: Prescription Growth Trends
ARISTADA®: Prescription Growth Trends Q4 year-over-year growth of 16% on TRx months of therapy (MOT) basis Outpaced overall atypical long-acting injectable (LAI) market Q4 year-over-year growth of 5% Market share: TRx MOT: 9.1% of atypical LAI market prescriptions in Q4 ‘20 ARISTADA Quarterly TRx MO
Slide 13: Advancing Neuroscience Development Programs
Advancing Neuroscience Development Programs Daily oral investigational antipsychotic designed to offer efficacy of olanzapine; addition of samidorphan intended to mitigate olanzapine-associated weight gain NDA resubmission and response to records request under review by FDA; PDUFA date June 1, 2021
Slide 14: Nemvaleukin Development Strategy
Nemvaleukin Development Strategy Demonstrate pharmacodynamic response Initiate phase 2 expansion stage Demonstrate monotherapy anti-tumor activity* Demonstrate anti-tumor activity in combination with PD-1 inhibitor* Select initial tumor types to pursue for registration of IV nemvaleukin Advance disc
Slide 15: www.alkermes.com
www.alkermes.com 15